Phase 3CompletedAge-related condition
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease (NOPARK)
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease: the NOPARK Study
- Sponsor
- Haukeland University Hospital (Academic or other)
- Enrolment
- 410 enrolled
- Conditions
- Parkinson Disease
- Interventions
- Nicotinamide Riboside; Placebo
- Ages
- adults, older adults
- Registry
- NCT03568968
Full record on ClinicalTrials.gov
From the registry
NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). A total of 400 persons with early stage Parkinson's disease will be enrolled, randomized on nicotinamide riboside (NR) 500mg x 2 per day or placebo, and followed for 52 weeks.
Primary outcomes
- Disease severity assessed by the total MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease rating Scale): sum of subsections I, II, and III
History
Last registry update
Primary completion
Started
Registered
Papers citing this trial
In the news
TrialsMedical Xpress (opens Medical Xpress in a new tab)
Nicotinamide riboside fails to show clinical benefit in yearlong Parkinson's trial
A JAMA study of 410 patients with early Parkinson's disease showed that nicotinamide riboside failed to provide clinical benefit over one year.
Also in JAMA (opens JAMA in a new tab), famtimes.co.kr (opens famtimes.co.kr in a new tab), N+1 (opens N+1 in a new tab), mdtoday.co.kr (opens mdtoday.co.kr in a new tab)